Cargando…
Comment on: Benchmarking tocilizumab use for giant cell arteritis
Autores principales: | Janagan, Shalini, Guly, Catherine, Skeoch, Sarah, Robson, Joanna C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479882/ https://www.ncbi.nlm.nih.gov/pubmed/36133959 http://dx.doi.org/10.1093/rap/rkac069 |
Ejemplares similares
-
Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis
por: Mazumder, Rifat, et al.
Publicado: (2021) -
Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. Reply
por: Karabayas, Maira
Publicado: (2021) -
Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply
por: Nakaoka, Yoshikazu, et al.
Publicado: (2020) -
Comment on: Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway
por: van Nieuwland, Marieke, et al.
Publicado: (2022) -
Comment on: Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway. Reply
por: Melville, Andrew R, et al.
Publicado: (2022)